Linkers and payloads are key components of Antibody-Drug Conjugates (ADCs), where linkers play a crucial role in connecting antibodies, active payloads, and the conjugation chemistry, significantly affecting the stability, safety, and efficacy of ADC drugs. Payloads, on the other hand, serve as the "magic bullet" of ADCs, with their physicochemical properties directly influencing the cytotoxicity of ADCs towards targeted cells. One of the main challenges in the development of ADCs to date is the insufficient stability of the linker-payload combination, which can lead to unintended payload release in the circulation system, causing off-target toxicity.
The linker-payload platform, known as Alphatecan, is independently developed by Alphamab Oncology with global intellectual property rights, addressing the efficacy and safety challenges of ADCs. Alphatecan features a hydrophilic linker and a Topoisomerase I (TopⅠ) inhibitor, offering distinct advantages over traditional TopⅠ inhibitors:
① Enhanced TopI inhibition activity and bystander effect, leading to increased cytotoxicity against tumor cells.
② Higher circulation stability, minimizing payload release in the bloodstream.
③ Superior antitumor activity and broader therapeutic window.
By integrating Alphatecan with other complementary technology platforms, Alphamab has brought together all the essential technologies necessary for developing proprietary and superior ADCs.
